文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

SIRPα变异错配与造血干细胞移植后慢性GVHD相关

Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

该研究纳入350例接受HLA全合亲缘造血干细胞移植的AML/MDS患者,发现39%的移植对存在SIRPα等位基因错配。

要点

  • SIRPα等位基因错配见于39%的HLA全合亲缘移植对。
  • SIRPα错配与慢性GVHD风险升高相关,尤其新发慢性GVHD。
  • SIRPα错配与较低复发率及更长无复发生存相关。

核心结论

  • SIRPα变异错配与造血干细胞移植结局相关,可能源于固有免疫同种识别。
  • SIRPα变异匹配可能为供者选择和移植风险分层提供有价值的信息。

研究设计与样本

  • 研究纳入350例接受HLA全合亲缘造血干细胞移植的急性髓系白血病/骨髓增生异常综合征患者。

主要发现

  • SIRPα等位基因错配存在于39%的移植对中。

临床怎么用

  • SIRPα变异匹配可能为供者选择和移植风险分层提供参考信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent compelling evidence showed that innate immune effector cells could recognize allogeneic grafts and prime an adaptive immune response. Signal regulatory protein α (SIRPα) is an immunoglobulin superfamily receptor that is expressed on myeloid cells; the interaction between SIRPα and its ubiquitously expressed ligand CD47 elicits an inhibitory signal that suppresses macrophage phagocytic function. Additional studies showed that donor-recipient mismatch in SIRPα variants might activate monocytic allorecognition, possibly as the result of non-self SIRPα-CD47 interaction. However, the frequency of SIRPα variation and its role in hematopoietic stem cell transplantation (HSCT) remains unexplored. We studied 350 patients with acute myeloid leukemia/myelodysplastic syndrome who underwent HLA-matched related HSCT and found that SIRPα allelic mismatches were present in 39% of transplantation pairs. SIRPα variant mismatch was associated with a significantly higher rate of chronic graft-versus-host disease (GVHD; hazard ratio [HR], 1.5; P = .03), especially de novo chronic GVHD (HR, 2.0; P = .01), after adjusting for other predictors. Those with mismatched SIRPα had a lower relapse rate (HR, 0.6; P = .05) and significantly longer relapse-free survival (RFS; HR, 0.6; P = .04). Notably, the effect of SIRPα variant mismatch on relapse protection was most pronounced early after HSCT and in patients who were not in remission at HSCT (cumulative incidence, 73% vs 54%; HR, 0.5; P = .01). These findings show that SIRPα variant mismatch is associated with HSCT outcomes, possibly owing to innate allorecognition. SIRPα variant matching could provide valuable information for donor selection and risk stratification in HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Saliba RM, Greenbaum U, Ma Q, et al. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv. 2021. PMID: 34495313. doi:10.1182/bloodadvances.2021004307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。